In a patient taking rosuvastatin 10 mg daily for mildly elevated LDL who has partial toe numbness extending to the heel and a known S1 radiculopathy, what mechanism can cause statin‑induced peripheral neuropathy, and is an oral glucose tolerance test indicated now?

Statin-Induced Peripheral Neuropathy: Mechanism and Evaluation

The evidence does not support a causal link between rosuvastatin and your patient's peripheral neuropathy symptoms. In fact, rosuvastatin may actually improve diabetic neuropathy rather than cause it, and an oral glucose tolerance test (OGTT) is indicated now to screen for diabetes—the most likely underlying cause of his symptoms.

Mechanism of Statin-Associated Neuropathy (When It Occurs)

The proposed mechanisms for statin-induced peripheral neuropathy remain poorly understood and controversial 1. When peripheral neuropathy does occur with statins, it appears to involve:

• Small fiber neuropathy affecting sensory and autonomic small fibers, causing burning, tingling, and dysesthesias 2
• Potential disruption of cholesterol synthesis in nerve membranes, though this mechanism is speculative
• Mitochondrial dysfunction in peripheral nerves (theoretical)

However, the actual risk appears minimal. A 2021 meta-analysis of 150,556 patients found no significant association between statin exposure and peripheral neuropathy risk (RR 1.26,95% CI 0.92-1.74) 3. The evidence quality is low, and when peripheral neuropathy occurs with statins, it should only be considered after excluding other etiologies 1.

Why This Patient's Neuropathy Is Unlikely Statin-Related

Rosuvastatin actually improves diabetic neuropathy through antioxidant mechanisms 4. In a randomized controlled trial, rosuvastatin 20 mg for 12 weeks:

• Improved neuropathy stage from 2a to 1b in diabetic patients
• Reduced neuropathic symptom scores from 4.5±2 to 2.4±1.8
• Improved peroneal nerve conduction velocity
• Reduced lipid peroxidation by 52% 4

The mechanism involves preservation of neuronal nitric oxide synthase (nNOS) and restoration of vasa nervorum (nerve blood supply), independent of cholesterol-lowering effects 5.

The Real Culprit: Undiagnosed Diabetes

Your patient's symptoms—partial toe numbness spreading to the heel with known S1 radiculopathy—are classic for diabetic peripheral neuropathy, not statin toxicity. The distribution (distal, symmetric, stocking pattern) and progression are pathognomonic for metabolic neuropathy.

Yes, an OGTT is absolutely appropriate now 6. Here's why:

• Peripheral sensory neuropathy is the single most common component cause for diabetic foot complications, present in 78% of diabetic patients with ulcerations 6
• Early detection of diabetes allows for glycemic control interventions that can prevent progression
• The patient has a clear risk profile requiring screening

Clinical Algorithm for This Patient

Immediate actions:

1. Order OGTT or HbA1c to screen for diabetes or prediabetes

2. Perform comprehensive foot examination including:

   • 10-g monofilament testing or Ipswich touch test
   • Pinprick, temperature, or vibration assessment
   • Vascular assessment with pedal pulses
   • Inspection for skin changes and deformities 6

3. Continue rosuvastatin 10 mg unless other compelling reasons exist—it is not causing his neuropathy and may actually be protective if he has undiagnosed diabetes

If diabetes is confirmed:

• Emphasize that glycemic control is the only disease-modifying treatment for diabetic neuropathy
• Schedule foot inspections at every visit given sensory loss 6
• Consider referral to podiatry for ongoing preventive care 6

If patient remains uncomfortable with rosuvastatin despite reassurance:

• Per Canadian guidelines, attempt rechallenge with same statin at same or lower dose (92% of patients successfully continue statins after rechallenge) 7
• If truly intolerant, try alternate-day or twice-weekly dosing of rosuvastatin 5-10 mg (achieves 23-43% LDL-C reduction) 7
• Switch to different statin only if above strategies fail
• Use non-statin adjuncts (ezetimibe, PCSK9 inhibitors) only as last resort 7

Critical Pitfalls to Avoid

Do not discontinue the statin based on unfounded neuropathy concerns. The cardiovascular benefits are firmly established 1, and the evidence suggests rosuvastatin may actually help diabetic neuropathy if present 5, 4.

Do not miss the diabetes diagnosis. The symptom pattern (distal sensory loss, stocking distribution, progression) combined with S1 radiculopathy suggests a metabolic/structural etiology, not drug toxicity.

Do not attribute every symptom to statins. The nocebo effect is powerful—patient anxiety about statins often causes more symptoms than the drug itself 7.